Robert Califf, MD, MACC, is the founding director of Duke Forge. Currently employed by Google and Verily Life Sciences (both Alphabet companies), Dr. Califf retired from his posts as Forge Director and Vice Chancellor for Health Data Science at Duke University in November of 2019. Dr. Califf remains an adjunct professor of medicine at both the Duke University School of Medicine and the Stanford University School of Medicine. Prior to serving as founding director of Duke Forge, Dr. Califf was appointed Commissioner of Food and Drugs for the U.S. Food and Drug Administration in 2016-2017 and served as Deputy Commissioner for Medical Products and Tobacco from February 2015 until his appointment as Commissioner in February 2016. Before joining the FDA, Dr. Califf was the Donald F. Fortin, MD, Professor of Cardiology and vice chancellor for clinical and translational research at Duke University. He also served as director of the Duke Translational Medicine Institute and founding director of the Duke Clinical Research Institute. A nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,200 publications in the peer-reviewed literature.
Dr. Califf is a Member of the National Academy of Medicine (formerly known as the Institute of Medicine (IOM)) in 2016, one of the highest honors in the fields of health and medicine. Dr. Califf has served on numerous IOM committees, and he has served as a member of the FDA Cardiorenal Advisory Panel and FDA Science Board's Subcommittee on Science and Technology. Dr. Califf has also served on the Board of Scientific Counselors for the National Library of Medicine, as well as on advisory committees for the National Cancer Institute, the National Heart, Lung, and Blood Institute, the National Institute of Environmental Health Sciences and the Council of the National Institute on Aging.
He has led major initiatives aimed at improving methods and infrastructure for clinical research, including the Clinical Trials Transformation Initiative (CTTI), a public-private partnership co-founded by the FDA and Duke. He also served as the principal investigator for Duke's Clinical and Translational Science Award and the NIH Health Care Systems Research Collaboratory coordinating center and co-PI of the Patient Centered Outcomes Research Institute Network.
Disclosures for Robert M. Califf, MD - 2018-2019
Dr. Robert Califf sits on the corporate board for Cytokinetics and is board chair for the People-Centered Research Foundation. He received personal fees for consulting from Merck, Amgen, Biogen, Genentech, Eli Lilly, and Boehringer Ingelheim. He was also employed as an advisor by Verily Life Sciences (Alphabet).